microdosing semaglutide for menopause GLP-1s: A New Approach to Hormonal and Metabolic Balance in Midlife People Are Microdosing Weight-Loss Drugs

mild: (025%), moderate: (26-50%), good: (51-75%), excellent: (76100%) Patients were followed-up for three months after the end of treatment period

Liraglutide, semaglutide and dulaglutide have demonstrated cardiovascular benefits, and Wegovy recently added to this evidence base: in the SELECT trial, patients on Wegovy had a 20% lower incidence of heart attack, stroke or death from heart disease compared to those on a placebo

Follow her on LinkedIn and ResearchGate.

It copies a hormone your gut naturally makes when you eat, controlling hunger signals, food consumption, and glucose levels

There is no long-duration safety signal dataset

Avoidant/Restrictive Food Intake Disorder (ARFID) ARFID involves a severe pattern of avoiding certain foods or selective eating that results in failure to meet nutritional needs without the body shape or body weight concerns central to anorexia nervosa